Roche Acquires Genentech Oncology Partner Piramed
This article was originally published in The Pink Sheet Daily
Executive Summary
$175 million deal nets Roche a novel program of signal transduction inhibitors with utility in cancer and inflammatory disease.
You may also be interested in...
Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
Gilead Springs Further Into Oncology With Calistoga Acquisition
Dominant in HIV, the biotech pays $375 million up front for Seattle-based Calistoga and its closely-watched PI3K program.
People In The News: Tracking The Latest Industry Personnel Moves
Presidents & CEOs